MapLight Therapeutics, Inc.
MPLT
Get informed when a big investor buys or sells
+ FollowMarket Cap$498.63M
Close$
$0.93
91.7% downside
Current Fair Value
91.7% downsideOvervalued by 91.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $498.63 Million |
|---|---|
| Enterprise Value | $448.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.66 |
| Beta | 2.65 |
| Outstanding Shares | 45,276,763 |
Return
| Return on Equity | -49.89% |
|---|---|
| Return on Assets | -47.63% |
| Return on Invested Capital | -51.72% |
Valuation & Multiples
| P/E Ratio | -2.57 |
|---|---|
| PEG | -1.5 |
| Price to Sales | - |
| Price to Book Ratio | 1.41 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.14 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 18, 2026
EPS Estimate
$-1.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 25,300▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 58.29%▲ 3.74% |
|---|---|
| Total Invested | $945.91M▲ 88.37% |
| Investors Holding | 109▲ 28.00% |
ESG Score
No data
About MapLight Therapeutics, Inc.
109 employees
CEO: Christopher A. Kroeger MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /...